Hydrochloric Acid → HCID 67456826, Verbindung
Reaktionsgleichung
[C:1]([CH2:3][C:4]1([N:17]2[CH:21]=[C:20]([C:22]3[N:27]4[CH:28]=[CH:29][N:30]=[C:26]4[CH:25]=[C:24]([C:31]4[CH:32]=[N:33][N:34]([CH3:36])[CH:35]=4)[N:23]=3)[CH:19]=[N:18]2)[CH2:9][CH2:8][N:7](C(OC(C)(C)C)=O)[CH2:6][CH2:5]1)#[N:2].C(Cl)[Cl:38].Cl.O1CCOCC1>>[ClH:38].[CH3:36][N:34]1[CH:35]=[C:31]([C:24]2[N:23]=[C:22]([C:20]3[CH:19]=[N:18][N:17]([C:4]4([CH2:3][C:1]#[N:2])[CH2:5][CH2:6][NH:7][CH2:8][CH2:9]4)[CH:21]=3)[N:27]3[CH:28]=[CH:29][N:30]=[C:26]3[CH:25]=2)[CH:32]=[N:33]1Komponenten
5
Versuchsvorschrift
Tert-butyl 4-(cyanomethyl)-4-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylate (Example 21; 17 mg, 0.035 mmol) was dissolved in DCM (170 μL, 0.035 mmol) and treated with 4N HCl in dioxane (170 μL, 0.70 mmol). After 90 minutes, the reaction mixture was concentrated in vacuo to afford 2-(4-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)piperidin-4-yl)acetonitrile hydrochloride (16 mg, 98% yield). MS (apci) m/z=388.3 (M+H).
Aufarbeitung
- concentrationthe reaction mixture was concentrated in vacuo
Quellen und Nachweise
- ORD-Eintrag
- ord-fd748c0d59cf4fd09070ff1f22da56a0
- Quelldatensatz
- uspto-grants-2015_02
- Patentnummer
- US08962596B2
Notizen zur Reaktion
Wird geladen…